精制血府胶囊对股腘动脉人工血管旁路术后通畅率的影响

目的 观察精制血府胶囊对下肢动脉硬化闭塞症（arteriosclerosis obliterans，AS0）患者股腘动脉搭桥后的临床疗效。方法 选择股腘动脉搭桥AS0患者38例（41条患肢），随机分为对照组18例（20条患肢），中药组20例（21条患肢）。所有患者均予华法林长期口服抗凝治疗，中药组给予精制血府胶囊口服，疗程为3个月。观察临床症状、凝血功能的变化情况，超声检测治疗后6、12个月人工血管通畅情况及踝肱指数（ankle arm index，AAI）。结果 手术后所有患者临床症状均明显改善。术后12个月间歇性跛行发生率中药组（20％，4／20例）较对照组（56％，10／18例）明显降低（P〈0．05）；截肢率中药组（5％，1／20例）低于对照组（17％，3／18例，P〈0．05）；术后12个月中药组人工血管通畅率（86％，18／21）较对照组（65％，13／20）显著增高（P〈0．05）；术后6个月、12个月中药组AAI（0．73±0．24、0．69±0．19）显著高于同期对照组（0．45±0．17、0．41±0，23，P〈0．05）。结论 精制血府胶囊可明显提高股腘动脉旁路术后12个月人工血管的通畅率，改善临床症状，缓解肢体缺血症状。

Effects of Refined Xuefu Capsule on Vascular Patency Rate after Femoral-popliteal Bypass

OBJECTIVE: To observe the effects of refined Xuefu Capsule (RXC) in patients with arteriosclerosis obliterans (ASO) after femoral-popliteal bypass (FPB). METHODS: Thirty-eight ASO patients with 41 limbs underwent FPB were randomly assigned to two groups: the control group (18 cases with 20 operated limbs) and the RXC group (20 cases with 21 operated limbs). All patients received long-term anticoagulant treatment with Warfarin, and RXC was given to the RXC group additionally for 3 months. Changes of clinical symptoms, blood coagulating function, as well as the condition of vascular patency and ankle arm index (AAI) were assessed 6 and 12 months after operation. RESULTS: Clinical symptoms were improved in all the patients after operation. One year after operation, incidence of intermittent claudication and amputation rate in the RXC group was 20% and 5 %, being lower than the respective rate (56% and 17%) in the control group (P < 0.05); the patency rate was 86% in the RXC group, being higher than that in the control group (65%, P<0.05). Six and 12 months after operation, AAI was 0.73 +/- 0.24 and 0.69 +/- 0.19 respectively in the RXC group, being significantly higher than that in the control group (0.45 +/- 0.17 and 0.41 +/- 0.23, P < 0.05) at the corresponding time points. CONCLUSION: RXC could obviously increase the patency rate 12 months after FPB, improve the clinical symptoms and alleviate the symptom of limb ischemia in ASO patients.